Printer Friendly

Pfizer receives FDA approval for the use of Vfend to treat esophageal candidiasis.

Pfizer, Inc., New York, NY, has received approval from the US Food and Drug Administration (FDA) to market Vfend (voriconazole), a broad spectrum antifungal medicine, for treatment of esophageal candidiasis. Candida organisms are normally found on the skin and mucous membranes of healthy individuals, but in people whose immune systems are weakened or compromised by organ transplants, cancer chemotherapy, or HIV/AIDS, Candida can multiply causing potentially dangerous infections.

The company notes that in immunocompromised patients, esophageal candidiasis may coat much of the surface of the mouth resulting in pain and difficulty swallowing and may ultimately progress to more serious, invasive disease.

Pfizer says the basis for the FDA approval was a clinical trial with immunocompromised patients conducted at study sites in 15 countries. Patients received either Vfend or fluconazole. Those treated with Vfend had success rates of 98%, compared to 95% for fluconazole, the company reports.

Vfend was initially approved in the US for the primary treatment of acute invasive aspergillosis and salvage therapy for rare but serious infections caused by the pathogens Scedosporium apiospermum and Flusarium spp. The company is continuing to study the use of Vfend for the treatment of serious fungal infections.

Contact: or
COPYRIGHT 2003 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Transplant News
Article Type:Brief Article
Geographic Code:1USA
Date:Nov 30, 2003
Previous Article:First liver transplants in Vietnam expected to be performed next year.
Next Article:Medtronic receives Humanitarian Device Exemption from FDA for heart repair product for children.

Related Articles
Evaluating Diagnosis and Treatment of Oral and Esophageal Candidiasis in Ugandan AIDS Patients.
Tenofovir: FDA Hearing October 3, Public Comment Deadlines September 26.
Fujisawa Healthcare gets FDA approval to use micafungin sodium for treating Candida infections in stem cell transplant patients.
Fujisawa, Roche to co-promote new product for treating systemic Candida infections.
Astellas Pharma new anti-fungal agent Mycamine is now available to physicians in US.
Pfizer receives FDA approval to market antifungal for treatment of candidemia.
Par Pharmaceutical licenses United States commercialization rights to antifungal Loramyc.
Strativa provides update on development status of pafuramidine and other in-licensed products.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters